Ratings by Rodman & Renshaw (Michael King Jr.)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/7/2026 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
2.28 (2.49) |
9.21% | Details | |
| 6/30/2026 | vTv Therapeutics | VTVT | New Coverage | Buy (N/A) |
36.27 (32.88) |
-9.35% | Details | |
| 6/15/2026 | Elicio Therapeutics | ELTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | Kyntra Bio | KYNB | New Coverage | Buy (N/A) |
6.63 (7.23) |
9.05% | Details | |
| 5/28/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
5.28 (4.42) |
-16.29% | Details | |
| 5/11/2026 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
3.51 (3.15) |
-10.26% | Details | |
| 4/15/2026 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
3.15 (2.25) |
-28.57% | Details | |
| 3/17/2026 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
1.54 (0.89) |
-42.21% | Details | |
| 3/9/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Buy (N/A) |
8.77 (9.51) |
8.44% | Details | |
| 3/9/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.63 (3.11) |
-73.26% | Details | |
| 1/13/2026 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
1.35 (1.11) |
-17.78% | Details | |
| 1/13/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
28.38 (18.74) |
-33.97% | Details | |
| 1/13/2026 | Biomea Fusion Inc. | BMEA | New Coverage | Buy (N/A) |
1.46 (1.28) |
-12.33% | Details | |
| 1/13/2026 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
0.31 (3.95) |
1174.19% | Details | |
| 1/13/2026 | Jasper Therapeutics | JSPR | New Coverage | Buy (N/A) |
1.48 (0.89) |
-39.86% | Details |
